跳到主要内容

新闻与日历

新闻: 截至 2026-10-09
这些标记是什么意思

重要性是模型对已发布报道给出的 1–5 分,不是对市场的预测。

已排定事件行上的影响是公司显著度层级(高/中由图谱中心度与规模判定;低仅用于人工整理的次要事件),不是对波动幅度的预测。

标记为已确认的财报日期,是 Yahoo Finance 认定由公司确认的;预估表示尚未公布。未加标记的行没有可查的出处记录。

经济数据发布属于宏观、不归属任何产业,因此在任何视图下都会保留。没有数值的发布表示尚未公布,页面会直说,而不是显示为零。

涵盖被追踪公司的即将到来的事件;已过去的事件会归档,并在可得时补上结果——这些结果都经人工整理并附引用,绝不杜撰。没有结果的历史行会显示“结果待定”。

解禁或指数调整的行会多出一行算术——将变得可卖出的股数,或指数基金必须买入的股数,以占流通股的比例表示——依据招股说明书或指数编制方法读出,两个数字都在该行注明出处。它陈述的是机制,不是价格走势。由 IPO + 180 天推算出的解禁日期会一直标为预估,直到公司自己说明为止。

未来

已排定 · 今天与明天 · 日历更新于 2026-10-12

10月12日周一 · 今天

10月13日周二

过往

已发布 · 最新在前

8月17日周一

产品

11:00
GlobeNewswire

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD

EyePoint released topline Phase 3 LUGANO data for DURAVYU (vorolanib intravitreal insert) in wet AMD. Per the release, "The primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset." The release adds that DURAVYU "was non-inferior to on-label aflibercept (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (>= 15 letters) unrelated to wet AMD," and reports a 42% reduction in treatment burden versus aflibercept (p-value <0.0001). The on-label 2 mg aflibercept comparator is Regeneron's Eylea; a missed head-to-head primary endpoint by the leading long-duration challenger is relevant to Regeneron's anti-VEGF franchise.

大盘 打开原文 ↗

产品

11:00
GlobeNewswire

Kratos and GE Aerospace's GEK800 wins USAF EMD contract as second-source JASSM engine, gets F143-ZZ-100 designation

Kratos Defense & Security Solutions and GE Aerospace announced that the GEK800 engine, which received the U.S. Military Engine Type Designation F143-ZZ-100, has been awarded a contract with the United States Air Force for the Engineering, Manufacturing and Development (EMD) of the turbofan as a second-source propulsion system for the Joint Air-to-Surface Standoff Missile (JASSM). The release states Kratos and GE Aerospace began working together in 2023 to complete a Technology Maturation and Risk Reduction (TMRR) phase including testing of the engine.

大盘 打开原文 ↗

合作

00:00
RTX

RTX's Raytheon awarded seven-year contract for Tomahawk cruise missiles

Raytheon, an RTX business, will accelerate production of Tomahawk cruise missiles for the U.S. Navy under a $22.9 billion seven-year contract awarded as part of the Department of War's Arsenal of Freedom, supporting an annual production ramp to more than 1,000 missiles.

大盘 打开原文 ↗

合作

00:00
NASA

NASA on-ramps Firefly Aerospace and L3Harris to $100 million Spacecraft Processing Operations Contract

NASA selected All Points Logistics LLC, Blue Origin LLC, Firefly Aerospace and L3Harris Technologies Inc. under the on-ramp provision of its Spacecraft Processing Operations Contract. The contract has a ceiling value of $100 million and a period of performance through February 1, 2033, and covers the facilities and services required to perform prelaunch processing of spacecraft and associated rocket hardware for delivery to the launch pad. The on-ramp lets these vendors furnish commercial payload processing for agency missions launching from locations where such capability was not available at the time of the initial award.

大盘 打开原文 ↗

8月16日周日

产品

01:15
GlobeNewswire

HII's Newport News Shipbuilding completes acceptance sea trials of carrier John F. Kennedy (CVN 79)

HII's Newport News Shipbuilding division completed acceptance sea trials of John F. Kennedy (CVN 79), the second Gerald R. Ford-class nuclear-powered aircraft carrier. HII said that with the successful completion of acceptance trials, the next step for the ship is preliminary acceptance, which will enable the Navy to begin underway test and evaluation of Kennedy's unique systems. Builder's sea trials had been completed earlier in 2026.

大盘 打开原文 ↗

原始消息流

所有到达的消息 · 7 天